You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: PAFOSPharma, LLC Topic: R41
PROJECT SUMMARY ABSTRACT In response to PAthis Phase I STTR proposal will aim at developing pharmacotherapies that can act aslife savermedications to counteract the neurotoxic effects of synthetic cannabinoidsSCsTowards this goalwe will synthesize CB R antagonists with fast onsets of action that can be administered in an emergency roomERsituationThe rationale is based on the successful soft agonis ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing CompoundsSBC: Initos Pharmaceuticals LLC Topic: NCATS
ABSTRACT The pathogenesis of Cystic FibrosisCFis caused by mutations in the gene for CFTRa cAMP activated chloride channel that regulates salt and water transport in epithelial tissuesespecially those in the airwaysRecent progress has resulted in small molecule therapeutic agents that partially correct defects in the CFTR protein due to certain mutationsHoweverin a substantial fraction of CF patie ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogenSBC: Arrevus, Inc. Topic: NIAID
Multi drug resistantMDRbacterial infections represent a significant threat to public healthIt is estimated that the impact of antibiotic resistance will continue to grow resulting in a global economic burden of $trillion and causingmillion deaths annuallyMany of the therapeutics currently under development represent traditional antibiotic approaches or next generation antibiotics that will likely ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Novel and potent SHIP1 inhibitors for improving hematologic recovery following myelosuppressive therapiesSBC: Alterna Therapeutics, Inc. Topic: NHLBI
ABSTRACT Despite recent advances in targeting cancer cellschemotherapy remains a mainstay of oncologyextending survival and providing cures for many types of cancerHoweverchemotherapy that ablates or suppresses bone marrow cells can be debilitating even when combined with autologous hematopoietic stem cell transplantationHSCTThe treatment causes severe side effects such as anemianeutropenia and th ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: ENGINEERING RESOURCES GROUP INC Topic: NIEHS
PROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: IMMUNOCHEM THERAPEUTICS LLC Topic: 102
PROJECT SUMMARY Cognitive decline and deterioration of long term cognitive performance are major side effects of CNS cancer treatmentBrain metastases are the most common CNS malignancies and a common cause of morbidity and mortality in aboutof all cancer patients with systemic diseaseaffecting overpatients in the US annuallyAs most systemic chemotherapy agents do not cross the blood brain barriert ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: PHAGEPRO, INC. Topic: NIAID
PROJECT SUMMARY Cholera is an acute and severe disease caused by the bacterium Vibrio cholerae that is spread primarily through contaminated water sources due to a lack of adequate sanitation infrastructure. The World Health Organization estimates that there are at least 3 million cases globally per year, 40 percent of which are spread through household transmission. Current prevention methods req ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: CELL MICROSYSTEMS INC Topic: 400
Project SummaryGenome wide functional genetics has been recently made possible by pooled library based CRISPR Casgene editing technologyBy randomly knocking out thousands of geneslarge scale screens can be conducted for functional geneticsdrug sensitivity and other phenotypesCurrently howeverthis forward genetic approach is largely relegated to live dead screens in mammalian cellsImproving the sop ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: MAKSCIENTIFIC Topic: 400
RESEARCH andampRELATEDUnitPROJECT SUMMARY ABSTRACT In response to PAthe aim of this Phase I STTR proposal is to optimize and develop peripherally actingcannabinoidreceptorCB Rneutral antagonists displaying favorable therapeutic profiles for treating diabetic nephropathyDNDN is a chronic diabetic kidney disease and affectstypeand typediabetic patientsIt is characterized by persistent albuminuria an ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: TRICORDER ARRAY TECHNOLOGIES LLC Topic: 100
PROJECT SUMMARY The for profit small business concernTricorder Array Technologies LLCwill developin partnership with the University of Alabama at BirminghamSIDECAReSensing and Integrating Data for Environmental Conditions in Animal ResearchThis device will automate collection of relevant data that will enhance consistency in animal models used to study human health treatment researchOur innovative ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health